The Down-regulation of SNCG Inhibits the Proliferation and Invasiveness of Human Bladder Cancer Cell Line 5637 and Suppresses the Expression of MMP-2/9

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Aug 13

PMID 32782717

Citations 2

Authors

Zhigang Chen

Fan Zhang

Shudong Zhang

Lulin Ma

Affiliations

Soon will be listed here.

Abstract

γ-synuclein (SNCG) is highly expressed in bladder cancer tissues and associated with tumor recurrence. However, the functional effect of SNCG on the development of bladder cancer remains unknown. In the present study, the effects of SNCG down-regulation by RNA interference (RNAi) on the proliferation and invasiveness of human bladder cancer cell line 5637 were explored. Three pairs of SNCG-specific small interference RNA (siRNA) were designed and transfected into the 5637 cell lines, and then the SNCG expressions in the three siRNA were assessed using reverse transcription-polymerase chain reactions (RT-PCR) and Western blot, while the cell proliferation and invasiveness of the 5637 cells were evaluated using cell counting kit-8 (CCK-8) and transwell assays, respectively. In addition, the expressions of matrix metalloproteinase-2 and -9 (MMP-2/9) were analyzed using enzyme-linked immunosorbent assays after the down-regulation of SNCG. The results showed that compared with the negative and empty vector controls, all three SNCG siRNAs were observed to significantly inhibit the SNCG expressions at the mRNA and protein levels (P < 0.05), among which the lowest SNCG expression was measured in SNCG-siRNA-244. And the SNCG suppression mediated by RNAi successfully inhibited the proliferation and invasiveness of the 5637 cell lines (P < 0.05), as well as the down-regulation of MMP-2/9. In conclusion, the proliferation and invasiveness of bladder cancer cells can be decreased by specifically interfering with the SNCG expression. And SNCG siRNA deserves further study as a novel target for biomedical therapy in bladder cancer.

Citing Articles

Machine learning developed an intratumor heterogeneity signature for predicting clinical outcome and immunotherapy benefit in bladder cancer.

Chen C, Zhang J, Liu X, Zhuang Q, Lu H, Hou J Transl Androl Urol. 2024; 13(7):1104-1117.

PMID: 39100839 PMC: 11291408. DOI: 10.21037/tau-24-5.

Anti-Tumor Mechanisms Associated With Regulation of Non-Coding RNA by Active Ingredients of Chinese Medicine: A Review.

Liu T, Hu S, Qiu Z, Liu D Front Oncol. 2021; 10:634936.

PMID: 33680956 PMC: 7930492. DOI: 10.3389/fonc.2020.634936.

References

Zhang C, Wang W, Lin J, Xiao J, Tian Y . lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. Int Braz J Urol. 2019; 45(3):549-559. PMC: 6786104. DOI: 10.1590/S1677-5538.IBJU.2018.0450. View

OLoughlin A, Woffindale C, Wood M . Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther. 2012; 12(4):262-74. DOI: 10.2174/156652312802083594. View

Jia T, Liu Y, Liu J, Shi Y . Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res. 1999; 59(3):742-7. View

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

Inaba S, Li C, Eric Shi Y, Song D, Jiang J, Liu J . Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat. 2005; 94(1):25-35. DOI: 10.1007/s10549-005-6938-0. View

Morgan J, Hoekstra A, Chapman-Davis E, Hardt J, Kim J, Buttin B . Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol. 2009; 114(2):293-8. DOI: 10.1016/j.ygyno.2009.04.036. View

Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C . Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 2005; 65(17):7635-43. DOI: 10.1158/0008-5472.CAN-05-1089. View

Gao J, Ding F, Liu Q, Yao Y . Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 2012; 376(1-2):21-32. DOI: 10.1007/s11010-012-1545-y. View

Ashihara E, Kawata E, Maekawa T . Future prospect of RNA interference for cancer therapies. Curr Drug Targets. 2010; 11(3):345-60. DOI: 10.2174/138945010790711897. View

10.

Zhang C, Gu L, Li X, Wang J . Silencing of inhibits human cervical cancer through the AKT signaling pathway. Cell Mol Biol Lett. 2019; 24:49. PMC: 6617888. DOI: 10.1186/s11658-019-0172-y. View

11.

Bjorklund M, Koivunen E . Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005; 1755(1):37-69. DOI: 10.1016/j.bbcan.2005.03.001. View

12.

Ye F, Wang L, Castillo-Martin M, McBride R, Galsky M, Zhu J . Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol. 2014; 2(1):1-14. PMC: 4219291. View

13.

Madersbacher S, Hochreiter W, Burkhard F, Thalmann G, Danuser H, Markwalder R . Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21(4):690-6. DOI: 10.1200/JCO.2003.05.101. View

14.

Shi Y, Chen Y, Dackour R, Potters L, Wang S, Ding Q . Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha. Am J Pathol. 2010; 177(2):964-73. PMC: 2913349. DOI: 10.2353/ajpath.2010.100061. View

15.

Ji H, Liu Y, Jia T, Wang M, Liu J, Xiao G . Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 1997; 57(4):759-64. View

16.

Zhao J, Xing N . Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry. Med Sci Monit. 2014; 20:2550-5. PMC: 4266204. DOI: 10.12659/MSM.892927. View

17.

Gupta A, Inaba S, Wong O, Fang G, Liu J . Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene. 2003; 22(48):7593-9. DOI: 10.1038/sj.onc.1206880. View

18.

Ha Y, Kim S, Kwon T, Chung S, Yoo E . Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer. Int Braz J Urol. 2019; 45(4):686-694. PMC: 6837591. DOI: 10.1590/S1677-5538.IBJU.2018.0530. View

19.

Holmang S, Hedelin H, Anderstrom C, Johansson S . The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995; 153(6):1823-6; discussion 1826-7. View

20.

Pan Z, Bruening W, Giasson B, Lee V, Godwin A . Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem. 2002; 277(38):35050-60. DOI: 10.1074/jbc.M201650200. View